Neurologic clinical trial - Roche/Genentech WN42636 "Luminesce" - WN42636

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS

Drug

SATRALIZUMAB

Phase

Phase 3

Condition

Generalized Myasthenia Gravis Myasthenia Gravis

Keywords

Roche | Genentech